Search

Displaying results 9331 - 9340 of 10000 in total
  1. Drug

    rhGAD65

    go.drugbank.com/drugs/DB04963
    Investigational

    rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.

  2. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-mo...

  3. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol (PEG) attachment to human growth h...

  4. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

  5. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.

  6. Drug

    Naluzotan

    go.drugbank.com/drugs/DB05562
    Investigational

  7. Drug

    TC-2696

    go.drugbank.com/drugs/DB05576
    Experimental

    Synonyms: 5-(5-METHOXY-3-PYRIDINYL)-N-METHYL-4-PENTEN-2-AMINE, (2S,4E)-
  8. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.

  9. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.

  10. Drug

    AL-02

    go.drugbank.com/drugs/DB06065
    Experimental